Cullinan Therapeutics Inc’s recently made public that its President and CEO AHMED NADIM unloaded Company’s shares for reported $99319.0 on Dec 23 ’25. In the deal valued at $10.01 per share,9,922 shares were sold. As a result of this transaction, AHMED NADIM now holds 420,699 shares worth roughly $4.26 million.
Then, Michaelson Jennifer sold 1,345 shares, generating $13,463 in total proceeds. Upon selling the shares at $10.01, the Chief Scientific Officer now owns 132,635 shares.
Before that, SUMER JACQUELYN L sold 3,480 shares. Cullinan Therapeutics Inc shares valued at $33,652 were divested by the Chief Legal Officer at a price of $9.67 per share. As a result of the transaction, SUMER JACQUELYN L now holds 135,432 shares, worth roughly $1.37 million.
UBS began covering CGEM with “Buy” recommendation on October 24, 2024. Stifel started covering the stock on May 01, 2024. It rated CGEM as “a Buy”.
Price Performance Review of CGEM
On Friday, Cullinan Therapeutics Inc [NASDAQ:CGEM] saw its stock fall -2.22% to $10.12. Over the last five days, the stock has lost -1.36%. Cullinan Therapeutics Inc shares have fallen nearly -17.05% since the year began. Nevertheless, the stocks have fallen -2.22% over the past one year. While a 52-week high of $13.33 was reached on 01/02/26, a 52-week low of $5.68 was recorded on 01/02/26.
Levels Of Support And Resistance For CGEM Stock
The 24-hour chart illustrates a support level at 9.81, which if violated will result in even more drops to 9.51. On the upside, there is a resistance level at 10.56. A further resistance level may holdings at 11.01.
How much short interest is there in Cullinan Therapeutics Inc?
A steep rise in short interest was recorded in Cullinan Therapeutics Inc stocks on 2025-12-15, growing by 0.14 million shares to a total of 6.82 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-14 was 6.68 million shares. There was a rise of 2.09%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on April 15, 2024 when William Blair began covering the stock and recommended ‘”an Outperform”‘ rating.
